{
    "clinical_study": {
        "@rank": "40313", 
        "acronym": "GABI-R", 
        "arm_group": {
            "arm_group_label": "Implantation of ABSORB Scaffold", 
            "description": "Patients suffering from coronary artery stenosis with an indication for implantation of ABSORB scaffold"
        }, 
        "brief_summary": {
            "textblock": "The German-Austrian ABSORB Register shall provide an analysis of acute and long-term safety\n      as well as therapy outcomes of the ABSORB (trade mark) bioresorbable vascular scaffold\n      system in patients suffering from coronary artery disease."
        }, 
        "brief_title": "Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold", 
        "completion_date": {
            "#text": "April 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Stenosis", 
        "condition_browse": {
            "mesh_term": [
                "Constriction, Pathologic", 
                "Coronary Stenosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The register collects prospective data regarding the quality of care of this  therapy\n      concept including specifically the following objectives:\n\n        -  Documentation of all consecutive patients having been treated with the ABSORB\n           biore-sorbable vascular scaffold system under clinical real-world conditions\n\n        -  Documentation of indications, procedural results, and short and long-term outcomes\n\n        -  Documentation of the technical performance of ABSORB implant procedures\n\n        -  Collection of safety data, in particular documentation of hospital mortality, major\n           non-fatal complications (especially myocardial infarction, Re-PCI (percutaneous\n           coronary intervention) or CABG (coronary artery bypass grafting), stroke, thrombosis)\n\n        -  Documentation of long-term patient safety marked by mortality and major non-fatal\n           complications (especially myocardial infarction, Re-PCI or CABG, stroke, thrombosis) at\n           30 days, 6 months, 2 years and 5 years\n\n        -  Gathering of health economics data (capture of direct costs, especially with view to\n           change of medication and outpatient/inpatient hospital services, and indirect costs)\n           pre and post ABSORB implant\n\n        -  Gathering data on the quality of life pre and post ABSORB implant to document\n           individual QoL dimensions as well as QALY (quality adjusted life year) data"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ABSORB implant scheduled\n\n          -  Age 18+\n\n          -  Patients giving consent to keep scheduled follow-ups\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "All patients in Germany and Austria having been implanted with ABSORB scaffold system"
            }
        }, 
        "enrollment": {
            "#text": "5000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066623", 
            "org_study_id": "GABI-R"
        }, 
        "intervention": {
            "arm_group_label": "Implantation of ABSORB Scaffold", 
            "description": "Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis", 
            "intervention_name": "ABSORB Scaffold", 
            "intervention_type": "Device", 
            "other_name": "ABSORBTM Everolimus-eluting Bioresorbable Vascular Scaffold"
        }, 
        "intervention_browse": {
            "mesh_term": "Everolimus"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "coronary artery stenosis, vascular scaffold, ABSORB", 
        "lastchanged_date": "February 17, 2014", 
        "location": [
            {
                "contact": {
                    "email": "gert.richardt@segebergerkliniken.de", 
                    "last_name": "Gert Richardt, Prof. Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Bad Segeberg", 
                        "country": "Germany", 
                        "zip": "23795"
                    }, 
                    "name": "Segeberger Kliniken GmbH"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "holger.nef@me.com", 
                    "last_name": "Holger Nef, Prof. Dr.", 
                    "phone": "+49 (0) 641-985-42101"
                }, 
                "facility": {
                    "address": {
                        "city": "Giessen", 
                        "country": "Germany", 
                        "zip": "35392"
                    }, 
                    "name": "University Clinic Giessen"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jan.torzewski@kliniken-oa.de", 
                    "last_name": "Jan S Torzewski, Prof. Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Kempten", 
                        "country": "Germany", 
                        "zip": "87439"
                    }, 
                    "name": "Herz- und Gef\u00e4\u00dfzentrum Oberallg\u00e4u/Kempten"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mb@klilu.de", 
                    "last_name": "Ralf Zahn, Prof. Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Ludwigshafen am Rhein", 
                        "country": "Germany", 
                        "zip": "67063"
                    }, 
                    "name": "Klinikum Ludwigshafen"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold System in Patients With Coronary Artery Stenosis", 
        "other_outcome": [
            {
                "description": "Effectiveness of ABSORB implantation will be assessed based on the following parameters:\n* Target vessel failure (TVF): This includes cardiac death, target vessel myocardial infarction (Q-wave or non-Q-wave MI) or clinically motivated target vessel revascularization (TVR), percutaneous or surgical.", 
                "measure": "Effectiveness of ABSORB implantation", 
                "safety_issue": "Yes", 
                "time_frame": "5 years follow-up period"
            }, 
            {
                "description": "Changes in quality of life will be assessed by measuring\nAngina pectoris scores (incl. CCS score, Canadian Cardiovascular Society score) and heart failure scores (NYHA, New York Heart Association score)\nStandardized questionnaire for quality of life (EQ-5D)\nStandardized questionnaire for health-related quality of life of patients with coronary artery disease (Seattle Angina Questionnaire, SAQ)", 
                "measure": "Change in quality of life", 
                "safety_issue": "No", 
                "time_frame": "5 years follow-up period"
            }, 
            {
                "description": "Health-economical effects will be assessed by measuring\nDirect costs: medication, visits to general practitioners and specialists, hospitalizations, inpatient and outpatient rehab, patient care services\nIndirect costs: disability, reduced earning capacity", 
                "measure": "Health-economical effects of ABSORB scaffold implantation", 
                "safety_issue": "No", 
                "time_frame": "5 years follow-up period"
            }
        ], 
        "overall_contact": {
            "email": "holger.nef@me.com", 
            "last_name": "Holger Nef, Prof. Dr.", 
            "phone": "+49 (0) 641-985-42101"
        }, 
        "overall_official": {
            "affiliation": "University Clinic Giessen and Kerckhoff-Clinic Bad Nauheim", 
            "last_name": "Christian Hamm, Prof. Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Ethics Commission", 
                "Austria: Austrian Society for Ultrasound in Medicine"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The following events will be evaluated:\nDeath\nMyocardial infarction\nClinically motivated target vessel revascularization\nComposite target parameter of the aforementioned events (MACE, major adverse cardiac event) as the primary target parameter\nStroke\nComposite target parameter of the aforementioned events including stroke as the primary target parameter (MACCE, major adverse cardiac and cerebrovascular event)\nStent thrombosis", 
            "measure": "Number of serious adverse cardiac events", 
            "safety_issue": "Yes", 
            "time_frame": "5 years after index procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066623"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The following parameters will be evaluated to assess procedural outcome:\nTechnical success: If the residual stenosis is less than 30% in the ABSORB covered lesion segment at the end of the procedure based on visual estimation\nTherapy success: Technical success and no periprocedural complications\nClinical success: Therapy success and no serious adverse cardiac (and cerebrovascular) events (MACE, MACCE)\nTIMI (thrombolysis in myocardial infarction) flow pre and post implant\nSudden occlusion of side branch in the case of bifurcation stenosis\nOptional: Quantitative coronary angiography (QCA) with index treatment: final in-scaffold and in-segment percentage diameter stenosis (%DS), reference vessel diameter", 
            "measure": "Success of ABSORB implantation", 
            "safety_issue": "Yes", 
            "time_frame": "during implantation of ABSORB scaffold"
        }, 
        "source": "IHF GmbH - Institut f\u00fcr Herzinfarktforschung", 
        "sponsors": {
            "collaborator": {
                "agency": "Abbott Vascular", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "IHF GmbH - Institut f\u00fcr Herzinfarktforschung", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "February 2014"
    }
}